Streetbeat News

Earnings

PUBM

A correction has been issued stating that PubMatic (PUBM) did not report its earnings today as previously announced.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 2:46 pm

PUBM

PubMatic (NASDAQ:PUBM) reported Q4 earnings of $0.34 per share, surpassing the consensus estimate of $0.30 by 13.33%. Quarterly sales were $56.24M, exceeding estimates of $47.54M by 18.30%.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 2:45 pm

BRZE

Braze shares are trading lower following the company's announcement of softer than expected earnings per share (EPS) guidance for the first quarter and the full fiscal year 2025.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 2:34 pm

BRZE

Braze has provided its financial guidance for Q1 and FY25, projecting adjusted EPS and revenue figures that are mixed in comparison to analyst estimates. For Q1, the adjusted EPS is expected to be between $(0.11) and $(0.10), worse than the $(0.05) estimate, with revenue projected at $131M-$132M, better than the $127.82M estimate. For FY25, the adjusted EPS is forecasted to be between $(0.12) and $(0.08), significantly below the $(0.02) estimate, while revenue is anticipated to be $570M-$575M, slightly below the $572.19M estimate.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 2:34 pm

SMTC

Semtech Corporation (NASDAQ:SMTC) is anticipated to report a Q4 loss of 3 cents per share, contrasting with a profit of 47 cents per share in the same quarter last year. Despite the expected loss, revenue is projected to increase to $196.46 million from $167.51 million year-over-year. Following better-than-expected Q3 earnings, Semtech's shares rose 10.7% to close at $27.86. Analysts from Baird, Susquehanna, Stifel, Needham, and Benchmark have recently updated their ratings and price targets for Semtech, with most maintaining positive outlooks.

Portfolio Pulse from Avi Kapoor

March 28, 2024 | 2:32 pm

AVTX

BDRX

GMDA

KOD

PMEC

XLO

U.S. stocks showed mixed performance with the Dow Jones slightly down, NASDAQ falling, and S&P 500 gaining. Avalo Therapeutics surged 435% after acquiring a Phase 2-ready anti-IL-1β mAb and announcing a significant private placement financing. Xilio Therapeutics soared 154% following an exclusive license agreement with Gilead Sciences. Biodexa Pharmaceuticals also saw a significant rise after promising results against brain cancers. Conversely, Primech Holdings, Gamida Cell, and Kodiak Sciences experienced notable declines. U.S. initial jobless claims dropped to 210,000, and the U.S. economy grew by 3.4% in Q4.

Portfolio Pulse from Avi Kapoor

March 28, 2024 | 2:32 pm

ROMJF

Rubicon Organics Inc. (OTC:ROMJF), a leading organic certified premium cannabis producer, reported a net revenue of $40.1 million for the year ended December 31, 2023, a 13% increase from the previous year. The company achieved its seventh consecutive quarter of positive Adjusted EBITDA and sixth consecutive quarter of positive operating cash flow, despite competitive pricing pressures and broader negative macroeconomic factors. Gross profit before fair value adjustments was $14.1 million, up 15% from 2022. The company's Wildflower brand is the top topical brand in Canada with a 21.8% market share. Looking ahead to 2024, Rubicon Organics is optimistic, particularly about the launch of full spectrum extract resin vapes under the 1964 Supply Co. brand.

Portfolio Pulse from Nicolás Jose Rodriguez

March 28, 2024 | 2:25 pm

DARE

Dare Bioscience (NASDAQ:DARE) reported Q4 earnings, beating estimates with an EPS of $-0.06 against an expected $-0.1. Revenue increased by $1.81 million year-over-year. The company had previously beaten EPS estimates last quarter, which was followed by a stable share price the next day.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 2:25 pm

DOOO

BRP Inc. (NASDAQ:DOOO) reported Q4 FY24 earnings with adjusted EPS of $1.82, missing expectations of $1.92, and revenues of $1.992 billion, below the $2.05 billion forecast. Year-over-year, revenues fell 12.5% due to lower volume across most product lines, impacted by late shipments, softening demand, and unfavorable winter conditions. Gross profit and margin, as well as Normalized EBITDA, also decreased. Despite this, BRP declared a quarterly dividend and provided FY25 revenue and EPS guidance below estimates, expecting a significant drop in Q1 2025 EBITDA. Shares rose 6.96% to $68.08.

Portfolio Pulse from Nabaparna Bhattacharya

March 28, 2024 | 2:16 pm

RUM

Rumble Inc (NASDAQ:RUM) reported Q4 financial results with a slight revenue increase of 2% year-over-year to $20.39 million, missing consensus estimates of $28.13 million. The company saw a loss of 14 cents per share, beating estimates for a loss of 22 cents. Despite a 16% quarter-over-quarter increase in average global monthly active users, average minutes watched per month slightly decreased. Rumble ended the quarter with $219.5 million in cash and equivalents. The company anticipates revenue growth starting Q2 and aims for breakeven by 2025. Oppenheimer analyst Jason Helfstein maintained a Perform rating on RUM.

Portfolio Pulse from Adam Eckert

March 28, 2024 | 2:11 pm